Lantern Bolsters Board With Columbia Care VP, Verano Taps M&A Pro, And Other Key Exec Moves
Top CEOs, investors and leaders in the cannabis industry will soon convene at the Benzinga Cannabis Capital Conference on Sept. 13-14 in Chicago.
Warren Buffett Turns 92: A Highlight For Each Decade Of His Life
Legendary investor Warren Buffett was born Aug. 30, 1930. The “Oracle of Omaha” turns 92 today and has lived through 10 decades.
Strategic Leadership Changes At Cannabis Firms: What’s New At Vertosa, Rubicon And Galexxy
Top CEOs, investors and leaders in the cannabis industry will soon convene at the Benzinga Cannabis Capital Conference on Sept. 13-14 in Chicago.
Inhibikase Shares Shoot Higher As FDA Announced Clearance To Blood-Cell Cancer Study
The U.S. Food and Drug Administration (FDA) has reviewed Inhibikase Therapeutics’ (NASDAQ: IKT) Investigational New Drug (IND) application and issued a Study May Procced (SMP) letter for its drug candidate IkT-001Pro in the treatment of Chronic Myelogenous Leukemia (CML).
Apellis Shares Show Mixed Reaction After Positive 2 Years Data From Late-Stage Retinal Disorder Study
Apellis Pharmaceuticals (NASDAQ: APLS) revealed top-line data readout at 24 months showing increased effects over time with intravitreal pegcetacoplan in the Phase 3 DERBY and OAKS studies in geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
KalVista Shares Climb As Late-Stage Label Extension Study On Skin Disorder Candidate Kicks-off
KalVista Pharmaceuticals (NASDAQ: KALV) has initiated the KONFIDENT-S open label extension (OLE) study for its ongoing Phase 3 study of sebetralstat for the on-demand treatment of hereditary angioedema (HAE) attacks.
Cue Biopharma Shares Decline Following Initial-Stage Metastatic Cancer Study Kicks-off
Cue Biopharma (NASDAQ: CUE) has dosed the first patient in a Phase 1 dose escalation study evaluating CUE-102 for the treatment of patients with Wilms' Tumor 1 (WT1)-positive recurrent/metastatic cancers.
Belite Bio Shares Gain On Initiation Of Late-Stage Retinal Disease Study
Belite Bio (NASDAQ: BLTE) has initiated enrollment for the U.S. Phase 3 clinical trial of its lead asset LBS-008 in patients with Stargardt Disease (STGD1), a progressively blinding disease with no approved treatment.
Warren Buffett Not Expected to Bid for Control of Occidental Following Approval for Bigger Stake
-Wall Street Journal
https://www.wsj.com/articles/warren-buffett-not-expected-to-bid-for-control-of-occidental-following-stake-boost-11661099924
Unrivaled Brands & Other Cannabis Operators Just Made Some Key Executive Changes You Should Know About
As Benzinga Cannabis Capital Conference returns on September 13-14 to Chicago, gathering top CEOs, investors and leaders in the industry, let's scroll through the latest leadership changes within the space.</